A comprehensive review of anti-diabetic activity of vanadium-based complexes via PTP-1B inhibition mechanism

Abstract

Inorganic salts of the vanadium have been found to mimic insulin in treating diabetic mellitus. In comparison to inorganic vanadium salts, complexes of vanadium with appropriate organic ligands can improve tissue absorption, efficacy, and reduce toxicity of the metal. An organic vanadyl derivative [bis(ethylmaltolato)oxovanadium(IV)] has been reported as a potential diabetes medication and is currently undergoing phase II clinical trials. The mechanism suggests that vanadium complexes inhibit the enzyme protein tyrosine phosphatase-1B(PTP-1B). Pharmacological, Biochemical and genetic evidences strongly suggest that inhibiting the PTP-1B enzyme could treat both diabetes and obesity, making PTP-1B an interesting target for drug development. Studies have also showed that the over expression of PTP-1B is involved in diabetic and obese patients and its inhibition may be an effective strategy in their treatment. Despite the fact that many natural PTP-1B inhibitors demonstrated promising clinical potential, there is no clinically used PTP-1B inhibitor, most likely due to low activity or a lack of selectivity. Search for more potent and selective PTP-1B inhibitors is still going on. As a result, inhibiting protein tyrosine 1B could be a new therapeutic option for patients at risk of type II diabetes mellitus and obesity. Many vanadium compounds are available as of now, as experimental probes for examining the mechanism of altered insulin action. However more studies are needed to establish its clinical use. Hence it has been proposed to prepare and characterize novel vanadium metal complexes with different coordination environments around vanadyl ion and check their anti diabetes activity.

Keywords

• Vanadium complex
• Drug-protein interaction
• BSA
• PTP-1B
• Serum glucose